The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $29,987,706 in first-year total cost, median $1,093,787.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (81)]4
- Neurological Sciences and Disorders K Study Section[NSD-K]2
- Special Emphasis Panel[ZNS1 SRB-G (05)]2
- Special Emphasis Panel[ZNS1 SRB-G (74)]2
- Special Emphasis Panel[ZNS1 SRB-G (10)]1
Most frequent institutions
- UNIVERSITY OF ROCHESTER3
- UNIVERSIDAD PERUANA CAYETANO HEREDIA2
- MASSACHUSETTS GENERAL HOSPITAL1
- MEDICAL UNIVERSITY OF SOUTH CAROLINA1
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | POINT: PLATELET-ORIENTED INHIBITION IN NEW TIA2U01NS062835-06 | EASTON, J. DONALDELM, JORDAN J.JOHNSTON, S. CLAIBORNE | UNIVERSITY OF TEXAS AT AUSTIN, TX | $11,826,732 | ZNS1 |
| 2016 | High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC1U01NS092764-01A1 | JUUL, SANDRA EWU, YVONNE W | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $2,231,942 | ZNS1 |
| 2016 | FOR-DMD: Double-blind randomized trial to optimize steroid regimen in Duchenne MD2U01NS061799-06 | BUSHBY, KATHERINE MARY DYMPNAGRIGGS, ROBERT C | UNIVERSITY OF ROCHESTER, NY | $1,946,015 | NSD |
| 2016 | High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) DCC1U01NS092553-01A1 | HEAGERTY, PATRICK J | UNIVERSITY OF WASHINGTON, WA | $291,139 | ZNS1 |
| 2016 | Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD2U01NS061795-06 | MCDERMOTT, MICHAEL PTAWIL, RABI | UNIVERSITY OF ROCHESTER, NY | $204,232 | NSD |
| 2015 | Phase 3 trial of inosine for Parkinson's disease CCC1U01NS090259-01A1 | SCHWARZSCHILD, MICHAEL A | MASSACHUSETTS GENERAL HOSPITAL, MA | $5,170,824 | ZNS1 |
| 2015 | Phase 3 trial of inosine for Parkinson's disease - DCC1U01NS089666-01A1 | OAKES, DAVID | UNIVERSITY OF ROCHESTER, NY | $1,093,787 | ZNS1 |
| 2015 | Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application1U01NS086974-01A1 | GARCIA, HECTOR HUGO | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $426,546 | ZNS1 |
| 2015 | Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application1U01NS086968-01A1 | LESCANO, ANDRES G | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $81,000 | ZNS1 |
| 2014 | Established Status Epilepticus Treatment Trial (ESETT)1U01NS088034-01 | CHAMBERLAIN, JAMESKAPUR, JAIDEEPSILBERGLEIT, ROBERT | UNIVERSITY OF VIRGINIA, VA | $6,170,975 | ZNS1 |
| 2014 | Established Status Epilepticus Treatment Trial (ESETT) - SDMC1U01NS088023-01 | ELM, JORDAN J. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $544,514 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.